LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Sarepta Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

17.55 -0.17

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.43

Max

17.84

Galvenie mērījumi

By Trading Economics

Ienākumi

644M

197M

Pārdošana

-134M

611M

P/E

Sektora vidējais

27.205

35.733

Peļņas marža

32.22

Darbinieki

1,372

EBITDA

543M

174M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+38.24% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

224M

1.9B

Iepriekšējā atvēršanas cena

17.72

Iepriekšējā slēgšanas cena

17.55

Ziņu noskaņojums

By Acuity

50%

50%

173 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Sarepta Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. jūl. 15:04 UTC

Galvenie tirgus virzītāji

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

2025. g. 21. jūl. 11:31 UTC

Galvenie tirgus virzītāji

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

2025. g. 31. marts 14:19 UTC

Galvenie tirgus virzītāji

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

2025. g. 11. aug. 11:48 UTC

Peļņas

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025. g. 11. aug. 11:11 UTC

Peļņas

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025. g. 29. jūl. 21:11 UTC

Peļņas

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

2025. g. 29. jūl. 12:14 UTC

Peļņas

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

2025. g. 29. jūl. 11:46 UTC

Peļņas

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

2025. g. 21. jūl. 12:53 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

2025. g. 21. jūl. 11:17 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

2025. g. 21. jūl. 10:25 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

2025. g. 21. jūl. 09:50 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025. g. 21. jūl. 09:12 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025. g. 17. jūl. 16:44 UTC

Peļņas

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

2025. g. 17. jūl. 13:48 UTC

Peļņas

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

2025. g. 17. jūl. 10:57 UTC

Peļņas

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

2025. g. 17. jūl. 09:08 UTC

Karstas akcijas

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

2025. g. 17. jūn. 09:10 UTC

Karstas akcijas

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025. g. 17. jūn. 08:59 UTC

Karstas akcijas

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025. g. 16. jūn. 08:55 UTC

Karstas akcijas

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Salīdzinājums

Cenas izmaiņa

Sarepta Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

38.24% augšup

Prognoze 12 mēnešiem

Vidējais 24.33 USD  38.24%

Augstākais 80 USD

Zemākais 5 USD

Pamatojoties uz 29 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sarepta Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

29 ratings

6

Pirkt

18

Turēt

5

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 62.47Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

173 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat